Hemophilia & Other Bleeding Disorders

Date: Friday, December 6, 2013
Time: 6:00 pm - 8:00 pm CT
Location: New Orleans Marriott, New Orleans, Louisiana
Room: Mardi Gras Ballroom (A — H)

Target Audience
This activity has been designed to meet the educational needs of hematologists, oncologists, registered nurses and other clinicians who are interested in the current issues related to urgent consultation with non-hematology healthcare providers (HCPs) on bleeding of undetermined cause, as well as registrants of the Blood CME Center.

Statement of Need/Program Overview
Acquired bleeding disorders due to inhibitor development and/or unexplained causes represent a significant challenge for clinicians and may be life-threatening for the patient.

Acquired hemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder caused by the development of autoantibodies directed against plasma coagulation factors, most frequently factor VIII. Autoantibodies against other factor proteins have also been reported. However, the severity of AHA at clinical presentation can make its management challenging, particularly among clinicians who do not routinely encounter patients with rare bleeding disorders.

Similarly, deficiencies of factor VII and factor XIII represent challenges in both diagnosis and management and may have a major impact on the outcome.

Educational Objectives
After completing this activity, the participant should be better able to:
  • Explain to non-hematology HCPs how to appropriately diagnose unexplained or unusual bleeding in hospitalized patients
  • Advise non-hematology HCPs about incorporating the most recent treatment guidelines for AHA and other unexplained bleeding in hospitalized patients
  • Discuss treatment advances for rare bleeding disorders (RBDs) with non-hematology HCPs, including new and emerging recombinant products
  • Explain the evolution and purpose of RBD registries to non-hematology HCPs, including the specific RBD registry findings on factor VII deficiency
  • Provide appropriate care and counsel for patients and their families

Chairman
Mark T. Reding, MD
Associate Professor of Medicine
Hematology, Oncology and Transplantation Division
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical School
Minneapolis, Minnesota

Presenting Faculty
Manuel Carcao, MD, MSc
Associate Professor
Pediatric Hematologist; Co-Director, Hemophilia Clinic
Hospital for Sick Children
University of Toronto
Toronto, Ontario, Canada

Miguel A. Escobar, MD
Department of Pediatrics and Internal Medicine
Division of Hematology
Associate Professor
University of Texas Health Science Center at Houston
University of Texas MD Anderson Cancer Center
Medical Director
Gulf States Hemophilia and Thrombophilia Center
University of Texas—Houston Medical School
Houston, Texas

Program Agenda

6:00 pm - 6:30 pm

Registration, pre-test, and dinner

6:30 pm - 6:50 pm

Introduction and Presentation 1
How I explain the interpretation of key coagulation lab values to non-hematology clinicians
Mark T. Reding, MD

6:50 pm - 7:10 pm

Presentation 2
How I would manage a patient with a prolonged aPTT with normal PT, low levels of factor VIII, and a raised inhibitor titer on Bethesda assay
Miguel A. Escobar, MD

7:10 pm - 7:30 pm

Presentation 3
How I would manage a patient with extensive bleeding, normal PT and aPTT, and an acquired factor XIII inhibitor
Mark T. Reding, MD

7:30 pm - 7:50 pm

Presentation 4
How I would manage a pediatric patient with extensive GI bleeding, a prolonged PT, elevated INR, and aPTT within the reference range
Manuel Carcao, MD, MSc

7:50 pm - 8:00 pm

Q&A and Conclusion
Panel


Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine, the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation
This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Fee Information
There is no registration fee for attending this symposium; however, seating is limited. Preregistration does not guarantee seating. We do recommend arriving at the symposium location early.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within 3 weeks (if applicable).

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Mark T. Reding, MD
Consulting Fees: Baxter, Bayer, Biogen Idec, GTC Biotherapeutics, Novo Nordisk, Octapharma; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Baxter, Novo Nordisk; Contracted Research: Bayer, Octapharma
Manuel Carcao, MD, MSc
Consulting Fees: Baxter, CSL Behring, Novo Nordisk, Octapharma; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Baxter, CSL Behring, Octapharma, Pfizer
Miguel A. Escobar, MD
Consulting Fees: Alnylam, Baxter, Biogen, Grifols, Kedrion, Novo Nordisk, Pfizer; Contracted Research: Baxter, Biogen, Grifols, Novo Nordisk, Pfizer
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager Reported Financial Relationship
PIM Clinical Reviewers: Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP
Have no real or apparent conflicts of interest to report.
ECM: Patrick J. Crowley, MBA, Managing Director; Denise Frontin, Senior Program Manager; Gay Boyle, MA, Chief Medical Writer
Have no real or apparent conflicts of interest to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Commercial Support
This activity is supported by an educational grant from Novo Nordisk Inc.




I have read the CME information.
Link to PIM Link to CMH Link to PIM Link to CMH Link to PIM Link to CMH Link to CMH Link to PIM Link to CMH Link to CMH register Eval Subscribe Hemophilia Bleeding Disorders Journal Club RSS Feed Hemophilia/Bleeding Disorders Journal Club Home